Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without Entinostat in MDS and AML
NCT00313586Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2006
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Aug 2006; status: completed.
02
Drugs
entinostat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00313586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313586.